1. A hypothesis of mesenchymal stem cell osteogenic differentiation mediated by chelidonic acid through the calcium import: original research and computer simulation.
- Author
-
Nasibov T, Gorokhova A, Porokhova E, Shupletsova V, Yurova K, Avdeeva E, Bariev U, Litvinova L, Belousov M, and Khlusov I
- Subjects
- Animals, Mice, Cells, Cultured, Mesenchymal Stem Cells metabolism, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects, Osteogenesis drug effects, Cell Differentiation drug effects, Computer Simulation, Calcium metabolism
- Abstract
Chelidonic acid (ChA) is small molecule capable of inducing the differentiation of mesenchymal stem cells (MSCs) into osteoblasts and the formation of mineralized bone matrix (MBM) both in vitro and in vivo. However, the molecular mechanisms underlying these effects are unknown. Therefore, in silico modelling of potential molecular targets of ChA was performed. ChA was isolated from Saussurea controversa. The ability of ChA to induce in vitro differentiation MSCs into osteoblasts synthesizing MBM was detected using alizarin red staining. ChA osteogenic activity was studied in mice by in situ test of ectopic osteogenesis, using the subcutaneous implantation of syngeneic bone marrow on the calcium phosphate coated titanium plates. DIGEP-Pred web service was used to simulate in silico the effect of ChA on gene expression, and overrepresentation analysis to search for common ontologies and pathways. ChA linearly increased the number of single (R
2 = 0.92, p = 0.039) and the total areas of MBM sites (R2 = 0.96, p = 0.019) in a 21-day MSC culture. Oral administration of ChA led to two to three times improved bone and bone marrow formation in situ. In silico modelling identified 306 genes (including 7 calcium import genes) and 9 signalling pathways potentially involved in ChA osteogenic effect and calcium metabolism in MSCs. In silico analysis revealed a list of key signalling pathways and genes for calcium influx into MSCs and their differentiation into osteoblasts as the first target candidates for studying real gene expression and molecular mechanisms of the ChA osteogenic effects., Competing Interests: Declarations. Conflict of interest: The authors declare no conflicts of interest. Ethical approval and consent to participate: Informed consent from the volunteers was obtained for the procedure, and the study was approved by the Local Ethics Committee of the Innovation Park of the Immanuel Kant Baltic Federal University (Permission Number 1 on February 28, 2019). The Local Ethics Committee of the Siberian State Medical University (approval number 6901 on 29 October 2018) approved the experimental study on animals. Consent for publication: Not applicable., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF